Table 3.
Pharmacologic Anticoagulant Agents Being Evaluated in Phase II or III Clinical Trials in Cancer Patients*
| Agent | Class/ MOA |
Route | Title | NCT Reference |
|---|---|---|---|---|
| Phase III | ||||
| Bemiparin vs placebo | LMWH | SC | CANBESURE Study (Cancer, Bemiparin and Surgery Evaluation) | NCT00219973 |
| Dalteparin vs SOC | LMWH | SC | A Study of Dalteparin Prophylaxis in High-Risk Ambulatory Cancer Patients | NCT00876915 |
| Dalteparin vs SOC | LMWH | SC | Dalteparin in Preventing Blood Clots in Patients With Lung Cancer | NCT00519805 |
| Dalteparin vs placebo | LMWH | SC | Dalteparin Low Molecular Weight Heparin for Primary Prophylaxis of Venous Thromboembolism in Brain Tumour Patients |
NCT00135876 |
| Gemcitabine with or without Dalteparin |
LMWH | SC | Gemcitabine With or Without Dalteparin in Treating Patients With Unresectable or Metastatic Pancreatic Cancer |
NCT00031837 |
| Gemcitabine or Capecitabine With or Without Dalteparin |
LMWH | SC | Gemcitabine With or Without Capecitabine and/or Dalteparin in Treating Patients with Metastatic Pancreatic Cancer |
NCT00662688 |
| Chemotherapy with or without Enoxaparin |
LMWH | SC | Chemotherapy With or Without Enoxaparin in Pancreatic Cancer (PROSPECT) |
NCT00785421 |
| Enoxaparin | LMWH | SC | Enoxaparin Thromboprophylaxis in Cancer Patients With Elevated Tissue Factor Bearing Microparticles |
NCT00908960 |
|
Enoxaparin vs intermittent pneumatic compression |
LMWH | SC | Japanese Efficacy and Safety Study of Enoxaparin in Patients With Curative Abdominal Cancer Surgery |
NCT00723216 |
| Chemotherapy with or without Enoxaparin |
LMWH | SC | Overall Survival of Inoperable Gastric/GastroOesophageal Cancer Subjects on Treating With LMWH + Chemotherapy (CT) vs Standard CT (GASTRANOX) |
NCT00718354 |
|
Fondaparinux with or without inferior vena cava filter |
Indirect factor Xa inhibitor |
SC | Anticoagulation and Inferior Vena Cava Filters in Cancer Patients With a Venous Thromboembolism |
NCT00423683 |
| Semuloparin vs placebo | ULMWH | SC | Evaluation of AVE5026 in the Prevention of Venous Thromboembolism in Cancer Patients Undergoing Chemotherapy (SAVE-ABDO) |
NCT00694382 |
| Tinzaparin | LMWH | SC | Effect of Low Molecular Weight Heparin: Tinzaparin in Lung Tumours (TILT) | NCT00475098 |
|
Tinzaparin vs Warfarin |
LMWH / VKA |
SC | Long-Term innohep® Treatment Versus a Vitamin K Antagonist (Warfarin) for the Treatment of Venous Thromboembolism (VTE) in Cancer |
NCT01130025 |
| Phase II | ||||
| Apixaban vs placebo | Direct factor Xa inhibitor |
Oral | A Phase 2 Pilot Study of Apixaban for the Prevention of Thromboembolic Events in Patients With Advanced (Metastatic) Cancer |
NCT00320255 |
| Combination chemotherapy with wafarin |
VKA | Oral | Combination Chemotherapy Plus Warfarin in Treating Patients With Prostate Cancer |
NCT00014352 |
| Gemcitabine with or without Dalteparin |
LMWH | SC | Gemcitabine With or Without Dalteparin in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer |
NCT00462852 |
| Dalteparin and Warfarin | LMWH / VKA |
SC / Oral |
The Catheter Study: Central Venous Catheter Sruvival in Cancer Patients Using Low Molecular Weight Heparin (Dalteparin) for the Treatment of Deep Vein Thrombosis |
NCT00216866 |
| Dalteparin | LMWH | SC | Fragmin in Ovarian Cancer: Utility on Survival (FOCUS) | NCT00239980 |
| Dalteparin | LMWH | SC | Treatment of Blood Clots in Children With Cancer | NCT00952380 |
| Enoxaparin | LMWH | SC | Identification and Treatment of Clinically Silent Catheter-Related Deep Vein Thrombosis in Children With Cancer |
NCT00633061 |
| Fondaparinux | Indirect factor Xa inhibitor |
SC | Fondaparinux in Preventing Blood Clots in Patients Undergoing Surgery for Gynecologic Cancer |
NCT00381888 |
| Tinzaparin | LMWH | SC | Tinzaparin for Primary Treatment and Extended Secondary Prophylaxis of Venous Thromboembolism in Patients with Cancer |
NCT00981903 |
| Tinzaparin | LMWH | SC | Tinzaparin in Treating Patients with Metastatic Kidney Cancer That Cannot Be Removed by Surgery |
NCT00293501 |
*
Search of www.clinicaltrials.gov August 21, 2009; search terms: “venous thromboembolism”, “thromboprophylaxis”, “thrombosis”, “phase II”, “phase III”; conditions = cancer. Completed studies and studies actively recruiting participants are included.
LMWH = low−molecular-weight heparin; SC = subcutaneous; SOC = standard of care; ULMWH = ultra−low-molecular-weight heparin.